The study demonstrates that CDRI-85/287 exerts its anti-proliferative and anti-invasive properties in ER negative breast cancer cells via preventing EGFR activation and subsequently inhibiting the tumor growth via inhibition PI-3-K/Akt and MEK/Erk pathways. Here, AKT1 is linked to neoplasm.